ArticleMicrobial biotechnology2025
Biotechnological Production, Isolation and Characterisation of (2R,3S)-2,3-Dihydroxy-2,3-Dihydrobenzoate.
Article in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biotechnological Production, Isolation and Characterisation of (2R,3S)-2,3-Dihydroxy-2,3-Dihydrobenzoate.Microbial biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Bacterial Rieske non-heme iron oxygenases catalyse the transformation of a wide range of aromatic compounds to vicinal cis-dihydrodiols. Such compounds have been successfully applied in chemoenzymatic synthetic routes for, for example, pharmaceuticals, natural products and polymers. In the case of benzoate, only (1S,2R)-cis-1,2-dihydroxy-2-hydrobenzoate is readily accessible via enzymatic transformation, but not the regioisomeric cis-2,3-dihydroxy-2,3-dihydrobenzoate (2,3-DD) or cis-3,4-dihydroxy-3,4-dihydrobenzoate. While trace amounts of putative cis-2,3-DD have been obtained before by using p-cumate 2,3-dioxygenase (PCDO) or a combination of chlorobenzene dioxygenase and nitrilase, none of these approaches enabled its production and isolation at a greater scale for potential use as a chiral building block in organic synthesis. We here provide a protocol for biotransformation of benzoate yielding (2R,3S)-2,3-dihydroxy-2,3-dihydrobenzoate using the PCDO of Pseudomonas citronellolis strain EB200 with negligible formation of side products. An isolation procedure suitable for production of the 2,3-DD sodium salt monohydrate at high purity (> 95%) at a gram scale, and a comprehensive characterisation of this novel metabolite is given.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.